Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib for advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma
ChiCTR2200062868Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dalpiciclib in well-differentiated liposarcoma (WDLS) and Liposarcoma, sponsored by Shandong Cancer Hospital. Primary endpoint: 12-week progression-free rate. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
dalpiciclib
03
Conditions
well-differentiated liposarcoma (WDLS)Liposarcoma
Beyond the preview
Go deeper on ChiCTR2200062868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062868.